Amiodarone Hydrochloride Injection

[02 October 2014]

Products Affected - Description

There are no products affected.

Reason for the Shortage

  • Hospira had amiodarone injection on shortage due to manufacturing delays.
  • Fresenius Kabi had amiodarone injection on shortage due to increased demand.
  • West-Ward stated the reason for the shortage was demand exceeding supply due to current market conditions.

Available Products

Amiodarone 50 mg/mL injection, Fresenius Kabi
3 mL vials, package of 10 (NDC 63323-0616-03)
9 mL vials, package of 10 (NDC 63323-0616-09)
Amiodarone 50 mg/mL injection, Hospira
3 mL ampules, package of 10 (NDC 00409-4348-35)

Amiodarone 50 mg/mL injection, Mylan Institutional
3 mL vials, package of 10 (NDC 67457-0153-03)
9 mL vials, package of 10 (NDC 67457-0153-09)
18 mL vials, package of 1 (NDC 67457-0153-18)

Amiodarone 50 mg/mL injection, Sagent
3 mL syringes (NDC 25021-0302-66)
Amiodarone 50 mg/mL injection, West-Ward
3 mL vial, package of 10 (NDC 00143-9875-10)
Nexterone premixed injection, Baxter
150 mg/100 mL premixed bags (NDC 43066-0150-10)
360 mg/200 mL premixed bags (NDC 43066-0360-20)

Estimated Resupply Dates

All presentations are available.

Related Shortages


October 2, 2014; September 22, 2014; August 21, 2014; July 17, 2014; June 26, 2014; June 12, 2014; May 27, 2014; May 12, 2014; May 8, 2014, University of Utah, Drug Information Service. Copyright 2014, University of Utah, Drug Information Service.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
ASHP Product Listing